Skip to main content
. 2019 Aug 30;23(11):7673–7684. doi: 10.1111/jcmm.14640

Figure 2.

Figure 2

SDF‐1‐AnxA5 binds to and activates CXCR4 and CXCR7 (A) The binding capacity of SDF‐1‐AnxA5 to CXCR4 was examined by pretreatment of MOLT‐4 cells with native SDF‐1‐AnxA5, SDF‐1 and AnxA5 at indicated concentrations. CXCR4 on the cell surface was detected by flow cytometry with anti‐human CXCR4‐PE antibody. The representative flow cytometry and line chart shows that SDF‐1‐AnxA5 and SDF‐1, but not AnxA5, had a dose‐dependent suppression of CXCR4 antibody binding to CXCR4 receptor (n = 3, **P < .01; ***P < .001 vs AnxA5 group). B, The effect of AnxA5, SDF‐1 and SDF‐1‐AnxA5 on p‐ERK and p‐AKT expression with or without the presence of CXCR4 specific antagonist, AMD3100 (n = 3, ***P < .001). C, qPCR analysis of CXCR7 knockdown efficiency by CXCR7 siRNA (n = 3, *P < .05 vs mock). D, The effect of SDF‐1‐AnxA5 and SDF‐1 on p‐AKT expression with or without silencing of CXCR7 (n = 3, ***P < .001; ****P < .0001)